Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 6 | 7 | 8 | 5 | 5 | 8 | 7 | 7 | 5 |
P/E ratio |
27.76 | 19.03 | 37.03 | 36.78 | 75.26 | 71.16 | 66.00 | 85.48 | 83.91 | 0.00 |
Altman Z-Score |
2.21 | 2.41 | 3.43 | 3.63 | 2.78 | 4.16 | 5.91 | 5.93 | 6.09 | 3.79 |
P/S ratio |
1.99 | 2.35 | 3.28 | 3.60 | 3.25 | 6.46 | 5.11 | 4.78 | 4.21 | 2.36 |
Altman Z″-Score (non-manufacturers) |
2.85 | 2.56 | 3.26 | 3.49 | 2.46 | 2.91 | 3.36 | 3.76 | 3.36 | 3.80 |
P/FCF ratio |
10.16 | 19.30 | 29.56 | 50.42 | 41.49 | 76.47 | 40.02 | 107.23 | 25.67 | 24.19 |
Beneish M-Score |
(2.81) | (2.64) | (2.42) | (2.73) | (2.71) | (2.57) | (2.92) | (2.73) | (3.19) | (3.20) |
P/Operating CF |
37.48 | 27.44 | 67.09 | 52.79 | 47.42 | 3,637.28 | 108.86 | 224.11 | 66.06 | 60.45 |
P/B ratio |
3.34 | 3.90 | 4.48 | 5.14 | 4.31 | 7.69 | 8.60 | 6.93 | 5.06 | 2.83 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 55.30 | 0.00 | 0.00 | 20.76 | 14.04 | 9.90 | 5.95 |
EV/Sales |
2.72 | 2.80 | 3.76 | 4.00 | 3.55 | 7.04 | 5.28 | 4.94 | 4.08 | 2.49 |
EV/EBITDA |
13.25 | 10.82 | 18.53 | 18.74 | 19.39 | 35.08 | 24.37 | 24.76 | 25.35 | 31.33 |
EV/Operating CF |
12.39 | 20.98 | 27.06 | 17.11 | 20.48 | 56.29 | 32.99 | 30.00 | 16.73 | 13.80 |
EV/FCF |
13.88 | 23.01 | 33.82 | 56.06 | 45.35 | 83.24 | 41.35 | 110.78 | 24.85 | 25.51 |
Quick Ratio |
1.64 | 0.88 | 1.28 | 1.84 | 0.95 | 1.26 | 1.10 | 1.50 | 0.86 | 1.38 |
Current Ratio |
2.95 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 | 2.20 | 2.44 | 1.35 | 2.42 |
Net Debt/EBITDA |
3.55 | 1.74 | 2.33 | 1.88 | 1.65 | 2.85 | 0.79 | 0.79 | (0.83) | 1.62 |
Debt/Assets |
50.90% | 37.59% | 36.33% | 38.98% | 30.08% | 37.95% | 24.11% | 25.30% | 4.80% | 20.47% |
Debt/Equity |
1.53 | 1.12 | 0.83 | 0.92 | 0.75 | 0.94 | 0.52 | 0.48 | 0.08 | 0.34 |
Asset Turnover |
0.55 | 0.59 | 0.63 | 0.62 | 0.54 | 0.56 | 0.78 | 0.77 | 0.73 | 0.69 |
Operating CF/Net income |
3.01 | 1.08 | 1.55 | 2.37 | 3.97 | 1.37 | 2.07 | 2.90 | 4.84 | (6.08) |
Capex/Depreciation |
(0.27) | (0.12) | (0.36) | (2.03) | (0.93) | (0.42) | (0.29) | (1.06) | (0.81) | (0.82) |
Interest Coverage |
5.46 | 22.76 | 12.67 | 10.67 | 4.72 | 5.33 | 6.38 | 8.43 | 12.41 | (2.39) |
| 12.03% | 18.83% | 13.22% | 14.72% | 5.86% | 12.05% | 12.20% | 7.75% | 6.11% | (3.60%) | |
| 4.02% | 7.22% | 5.69% | 6.08% | 2.36% | 5.15% | 6.02% | 4.38% | 3.68% | (2.05%) | |
ROIC |
5.53% | 9.66% | 6.53% | 7.57% | 4.81% | 4.56% | 8.55% | 6.36% | 5.56% | (1.42%) |
Return on Tangible Assets |
11.34% | 26.16% | 15.07% | 13.92% | 7.58% | 12.08% | 13.14% | 8.04% | 9.72% | (4.22%) |
Average Days of Receivables |
59.33 | 54.36 | 57.60 | 55.95 | 58.57 | 53.49 | 61.00 | 69.80 | 61.06 | 62.89 |
Research and Development Expense of Revenue |
4.48% | 4.61% | 4.16% | 4.29% | 4.71% | 3.77% | 3.12% | 3.69% | 4.34% | 4.24% |
Selling, General and Administrative Expense of Revenue |
33.16% | 32.10% | 32.83% | 32.23% | 34.25% | 31.62% | 28.53% | 28.26% | 35.02% | 34.05% |
Intangible Assets out of Total Assets |
0.46 | 0.43 | 0.44 | 0.38 | 0.42 | 0.46 | 0.27 | 0.27 | 0.30 | 0.31 |
Share Based Compensation of Revenue |
2.54% | 2.18% | 2.16% | 2.19% | 2.45% | 2.93% | 2.07% | 1.78% | 1.44% | 1.03% |
Graham Net Nets |
(0.29) | (0.22) | (0.11) | (0.08) | (0.11) | (0.07) | (0.02) | (0.01) | 0.01 | 0.01 |
Graham Number |
27.77 | 35.01 | 31.23 | 28.56 | 16.66 | 22.51 | 19.84 | 17.50 | 16.61 | 0.00 |
Earnings Yield |
3.60% | 5.26% | 2.70% | 2.72% | 1.33% | 1.41% | 1.52% | 1.17% | 1.19% | (1.23%) |
Free Cash Flow Yield |
9.85% | 5.18% | 3.38% | 1.98% | 2.41% | 1.31% | 2.50% | 0.93% | 3.90% | 4.13% |
Revenue per Share |
28.28 | 27.04 | 25.82 | 23.01 | 19.46 | 17.17 | 19.50 | 18.78 | 17.13 | 17.20 |
Operating CF per Share |
6.22 | 3.61 | 3.58 | 5.38 | 3.37 | 2.15 | 3.12 | 3.09 | 4.18 | 3.10 |
Capex per Share |
(0.67) | (0.32) | (0.72) | (3.74) | (1.85) | (0.69) | (0.63) | (2.25) | (1.37) | (1.42) |
Free Cash Flow per Share |
5.55 | 3.29 | 2.87 | 1.64 | 1.52 | 1.45 | 2.49 | 0.84 | 2.81 | 1.68 |
Cash per Share |
5.20 | 6.10 | 3.53 | 5.60 | 5.08 | 3.79 | 2.71 | 3.29 | 3.42 | 2.71 |
Shareholders Equity per Share |
16.88 | 16.31 | 18.93 | 16.11 | 14.68 | 14.43 | 11.58 | 12.96 | 14.26 | 14.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.88 | 16.31 | 18.93 | 16.11 | 14.68 | 14.43 | 11.58 | 12.96 | 14.26 | 14.35 |
Free Cash Flow |
261.82 | 165.70 | 145.44 | 83.34 | 77.78 | 73.58 | 126.23 | 43.13 | 148.31 | 86.43 |
Working Capital |
552.28 | 356.86 | 468.52 | 517.91 | 313.77 | 440.05 | 328.82 | 340.36 | 136.47 | 298.85 |
Capital Expenditures |
(31.40) | (16.02) | (36.31) | (189.72) | (94.49) | (35.22) | (31.98) | (116.15) | (72.04) | (73.31) |
Net Current Asset Value |
(764.73) | (695.14) | (466.73) | (347.11) | (354.28) | (394.71) | (76.36) | (30.78) | 36.27 | 10.93 |
EV/EBIT |
23.18 | 17.19 | 29.83 | 29.94 | 43.68 | 68.25 | 50.51 | 57.19 | 65.64 | 0.00 |
Capex to Sales |
0.02 | 0.01 | 0.03 | 0.16 | 0.10 | 0.04 | 0.03 | 0.12 | 0.08 | 0.08 |
Price to Operating Income |
16.97 | 14.42 | 26.08 | 26.93 | 39.97 | 62.70 | 48.88 | 55.36 | 67.79 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.38 | 0.46 | 0.32 | 0.30 | 0.39 | 0.39 | 0.44 | 0.32 | 0.27 | 0.28 |
Cash ROIC |
11.58% | 8.09% | 7.51% | 4.49% | 4.96% | 4.56% | 12.26% | 3.72% | 14.95% | 7.63% |
Accounts Receivable Turnover |
6.36 | 6.65 | 6.79 | 6.90 | 6.92 | 5.95 | 5.64 | 5.76 | 5.95 | 5.72 |
Accounts Payable Turnover |
9.26 | 8.72 | 9.00 | 9.05 | 8.98 | 9.36 | 8.83 | 9.27 | 10.02 | 12.28 |
Inventory Turnover |
1.63 | 1.79 | 2.14 | 2.00 | 1.58 | 1.59 | 2.17 | 3.10 | 2.91 | 2.79 |
Average Days of Payables |
34.10 | 39.97 | 43.36 | 42.15 | 43.69 | 38.84 | 36.74 | 42.05 | 41.00 | 30.90 |
Days of Inventory on Hand |
204.64 | 217.82 | 187.49 | 171.03 | 219.31 | 249.15 | 195.75 | 128.96 | 119.29 | 127.22 |
Average Receivables |
209.76 | 204.61 | 192.85 | 169.26 | 143.47 | 146.38 | 175.12 | 168.13 | 151.95 | 154.89 |
Average Payables |
59.03 | 70.18 | 68.64 | 61.15 | 54.33 | 50.51 | 57.05 | 59.31 | 49.12 | 41.32 |
Average Inventory |
335.76 | 341.17 | 288.29 | 276.20 | 307.82 | 296.45 | 232.31 | 177.57 | 168.86 | 181.98 |
Average Assets |
2,423.44 | 2,323.27 | 2,065.21 | 1,897.28 | 1,839.83 | 1,543.52 | 1,270.94 | 1,256.05 | 1,238.02 | 1,278.92 |
Average Common Equity |
808.58 | 890.40 | 888.98 | 783.71 | 740.55 | 659.39 | 627.49 | 710.15 | 746.02 | 730.59 |
Columns are period end dates